Safety and Efficacy of Intralesional 0.5% Triamcinolone Acetonide in 0.2% Fluconazole Solution vs 0.1% Topical Mometasone Furoate With 2% Miconazole Nitrate Cream in the Treatment of Chronic Paronychia: An Intraindividual Randomized Controlled Trial.

NCT ID: NCT07311759

Last Updated: 2025-12-31

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 21 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-08-17
• Study Completion Date: 2026-05-31

Brief Summary

Our objective is to compare the efficacy and safety of intralesional corticosteroids + fluconazole solution to corticosteroid with an antifungal topical preparation, in the management of chronic paronychia.

Detailed Description

Chronic paronychia (CP) is defined as inflammation of the nail fold(s) of more than 6 weeks duration (Shafritz and Coppage, 2014). It is now considered as a form of hand eczema, caused primarily by irritation of the nail folds by environmental allergens. This leads to recurrent inflammation of nail folds, followed by fibrosis and inability to generate the cuticle, ending in loss of the waterproof seal, moisture retention, and compromise of blood supply due to fibrosis. These can explain why CP is commonly resistant to topical and even systemic treatments. Candida infection is thought to be a secondary event in a subset of cases (Relhan and Bansal, 2022), with positive fungal culture in about 56.1% of cases (Bahunuthula et al., 2015) Important risk factors for the development of CP include occupations with excessive exposure to moisture and irritants (e.g. housewives, cooks, and health care providers), immunosuppression (e.g. diabetes mellitus and HIV); due to increased risk of secondary colonization, and some medications (e.g. retinoids) (Relhan and Bansal, 2022). A higher incidence of contact sensitization and Candida hypersensitivity in these patients has been reported, (Bahunuthula et al., 2015) thus candidal control may be of help to ameliorate the disease.

Clinically, CP presents with erythema, pain and swelling of one or more of the nail folds for >6 weeks. It generally affects multiple fingernails, more commonly, of the dominant hand. Nail matrix may be secondarily affected leading to transverse ridging, discoloration, Beau's lines, or onychomadesis (Shafritz and Coppage, 2014, Atiş et al.,2018). The last updated severity scale for CP has been proposed in 2018, taking into account the number of affected nail folds, erythema, edema, nail plate and cuticle changes (Atiş et al.,2018).

Management of CP relies mainly on avoidance of the irritants and topical corticosteroids which are now considered the mainstay of treatment (Shafritz and Coppage, 2014). Systemic antifungals are used in cases with associated candida infection (Tosti et al., 2002).

Intralesional steroid injection, in the form of monthly injections of triamcinolone acetonide (2.5- 10 mg/mL), is used for the treatment of nail psoriasis, nail lichen planus and twenty-nail dystrophy. It is, however, scarcely mentioned in literature in the management of CP (Baran, 2001). In addition, the optimal treatment regimen and injection technique have not yet been established, and no recent relevant studies exist.

Surgical treatment is reserved for cases of CP of more than 6-month duration, that has been resistant to medical treatment (Relhan et al., 2014)

Conditions

Chronic Paronychia

Keywords

Intralesional triamcinolone; Chronic paronychia; Intralesional fluconazole

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Intralesional Triamcinolone acetonide and fluconazole

The proximal nail fold is cleansed with alcohol. Triamcinolone acetonide and fluconazole in the ratio of 1:7, yielding a triamcinolone acetonide concentration of 5mg/ml, is injected through the affected nail fold with a 30-gauge, 1-mL insulin syringe needle. The nail fold is divided into 2 halves and a maximum of 0.5 cc is injected in both halves or till there is swelling /edema of the nailfold. Injections are administered every 4 weeks until the end of treatment response, or for a maximum of 3 months

Group Type: ACTIVE_COMPARATOR

Intralesional triamcinolone acetonide and fluconazole

Intervention Type: DRUG

Triamcinolone acetonide and fluconazole in the ratio of 1:7, yielding a triamcinolone acetonide concentration of 5mg/ml, is injected through the affected nail fold with a 30-gauge, 1-mL insulin syringe needle.

Topical treatment with mometasone furoate and miconazole nitrate

Topical treatment in the form of twice daily application of combined steroid and antifungal (mometasone furoate and miconazole nitrate, Elica-M®) till the end of treatment response or for a maximum of 3 months.

Group Type: ACTIVE_COMPARATOR

Topical mometasone furoate and miconazole nitrate, Elica-M®

Intervention Type: DRUG

Topical treatment in the form of twice daily application of combined steroid and antifungal (mometasone furoate and miconazole nitrate, Elica-M®) till the end of treatment response or for a maximum of 3 months.

Interventions

Intralesional triamcinolone acetonide and fluconazole

Triamcinolone acetonide and fluconazole in the ratio of 1:7, yielding a triamcinolone acetonide concentration of 5mg/ml, is injected through the affected nail fold with a 30-gauge, 1-mL insulin syringe needle.

Intervention Type: DRUG

Topical mometasone furoate and miconazole nitrate, Elica-M®

Topical treatment in the form of twice daily application of combined steroid and antifungal (mometasone furoate and miconazole nitrate, Elica-M®) till the end of treatment response or for a maximum of 3 months.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Patients with chronic paronychia affecting ≥ 2 fingernails in the dominant hand.

2. Patients not receiving any relevant systemic treatment for at least 4 weeks before initiation of our study

3. Patients not receiving any relevant topical treatment for at least 2 weeks before initiation of our study

Exclusion Criteria

1. Patient with peripheral vascular disease or Raynaud's phenomenon

2. Pregnant and lactating females

3. Patients with autoimmune diseases e.g., connective tissue diseases, psoriasis, reactive arthritis, and pemphigus.

4. Patients with solid or hematological malignancies.

5. Patients on systemic drugs that are known to cause chronic paronychia e.g. retinoids.

6. Patients with any visible focus of infection at the injection site or in the vicinity, including patients with superimposed attack of acute paronychia.

7. Onychomycosis or any associated nail disease

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Cairo University

OTHER

Sponsor Role: lead

Responsible Party

Basant Ahmed Mohamed Abdelaal Helal

Dermatology Specialist

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Yousra A Azzazi, Lecturer of Dermatology

Role: STUDY_DIRECTOR

Cairo University

Mohamed M El-Komy, Professor of Dermatology

Role: STUDY_CHAIR

Cairo University

Habiba K Edrees, Dermatology Resident

Role: PRINCIPAL_INVESTIGATOR

Cairo University

Khadija A Affify, Dermatology resident

Role: PRINCIPAL_INVESTIGATOR

Cairo University

Locations

Cairo University

Cairo, , Egypt

Countries

Egypt

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

N-255-2024

Identifier Type: -

Identifier Source: org_study_id